Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist "DABI-F"

Completed

Phase N/A Results N/A

Trial Description

To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.

Conditions

Interventions

  • Vitamin K antagonist Drug
    Intervention Desc: As prescribed by treating physicians
    ARM 1: Kind: Experimental
    Label: Vitamin K antagonist
    Description: Non-valvular atrial fibrillation patients who were initiated on VKA for stroke prevention.
  • Dabigatran (Pradaxa) Drug
    Intervention Desc: As prescribed by treating physicians
    ARM 1: Kind: Experimental
    Label: Dabigatran
    Description: Non-valvular atrial fibrillation patients who were initiated on dabigatran for stroke prevention.

Trial Design

  • Observation: Cohort
  • Perspective: Retrospective
  • Sampling: Non-Probability Sample

Trial Population

Patients with non-valvular atrial fibrillation (NVAF).

Outcomes

Type Measure Time Frame Safety Issue
Primary Incidence of Hospitalization Events (composite endpoint) Within 2 years of starting treatment Yes

Sponsors